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A B S T R A C T
Stroke remains the third leading cause of mortality in developed countries despite
declining tendency over the past decades. As the leading cause of disability and second
cause of dementia, primary prevention should be the main way to fight the disease, since
therapy is not efficient enough. Several observations pointed to estrogen as a protective
agent that may reduce stroke risk, however, studies have shown conflicting data. There
is no strong evidence that hormone replacement therapy (HRT) increases stroke risk.
Several studies have shown that HRT may reduce the risk of fatal stroke. Conflicting re-
sults have been found for Alzheimer’s disease and HRT as well. An association between
higher serum concentration of estradiol and decreased risk of cognitive decline has been
found in some studies, supporting the hypothesis that estrogen concentration may play
a significant role in brain protection. Having in mind results of recent randomized tri-
als, it is suggested that HRT should not be recommended on general basis for the pri-
mary or secondary prevention of cardiovascular/cerebrovascular diseases or for pri-
mary prevention of degenerative diseases such as Alzheimer’s disease. Osteoporosis,
cognitive decline and climacteric symptoms that are likely to impact on quality of life,
speak in favor for recommendation of HRT use. On the other side, family history of
breast carcinoma, mastopathy, thromboembolism, in certain cases gallbladder disease,
will discourage the commencement of HRT. Respecting the patient’s preferences and
having benefits and risks in mind as well as science advisory statements, individual
counseling regarding HRT should be the leading concept in the healthcare of postmeno-
pausal women.
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Introduction
The ovaries produce estradiol and pro-
gesterone on a cyclic schedule from pu-
berty to menopause. These hormones have
significant influence not only on sexual
target organs such as the uterus, breast,
vagina and skin, but also on the brain,
urinary tract, kidneys, liver, bones, myo-
cardium and arterial walls. Human ova-
ries stop secreting hormones when wo-
men are approximately 50 years of age.
However, more than 50% of these post-
menopausal women are able to synthe-
size estradiol outside the ovaries and do
not experience the full consequences of
estradiol deprivation1–3.
Symptoms that occur during the cli-
macteric phase of a woman’s life may be-
gin premenopausally or long before her
last menstrual period. The onset of these
symptoms fluctuates between the early
forties and late fifties. The hormonal treat-
ment of menopausal women has been con-
troversial: what to give, when to start
and for how long are the questions that
physicians still need answers for.
Since the 60s, efforts have been made
to identify and offer exogenous replace-
ment of ovarian estradiol to women at
risk of estrogen deficiency. Hormone re-
placement therapy aims to restore physi-
ological levels of estrogen, in order to pre-
vent estrogen deficiency symptoms and
diseases resulting from the menopause.
The benefits of estrogen replacement may
be modified by the addition of progeste-
rons, which are necessary to protect the
endometrium in a woman with an intact
uterus. In recent years, an increasing num-
ber of different estrogen formulations and
doses have become available.
The need for improving the quality of
life for postmenopausal women has be-
come a serious matter in medical care.
Longevity has naturally improved, and
with it, quality has become considerably
more important.
Although HRT has been available for
50 years, the indications for its use have
gradually widened from relief of current
menopausal symptoms to prevention of
future osteoporotic fractures or coronary
heart disease.
Benefits attributed to the use of HRT:
1. Menopausal symptoms – a positive
effect of estrogen treatment on symptoms
such as hot flushes, sleep disturbances,
asthenia, mood instability, vaginal dry-
ness and urinary tract infection can be
expected
2. Bones – important part of preven-
tive medicine in reducing bone loss in the
short term and risk of fracture in the long
term; the benefits appear to be restricted
only to current users, since never and
past users had similar fracture risks 5–
10 years after HRT was stopped4.
3. Plasma lipids – estrogens induce in-
crease of HDL cholesterol and decrease of
LDL cholesterol5, estrogen reduces plas-
ma levels of apolipoprotein E.
4. Artery intima-media thickness (IMT)
– intima media thickness can be mea-
sured by high-resolution ultrasound, chan-
ges are correlated with atherosclerotic
progression. HRT may influence the IMT
in women over 65 years6,7. However, re-
cent data are conflicting. A trial of post-
menopausal women with increased IMT
showed that treatment with estrogen (with
or without progestin) had no effect on the
progression of carotid IMT despite signif-
icant beneficial effects on LDL and fibri-
nogen8.
5. Plaque formation may also be re-
duced by the modification of the inflam-
matory response by estrogen, via its ef-
fects of interleukin 6, a cytokine postu-
lated to participate in plaque formation9.
Estrogen has also been found to have an-
tioxidant properties via its action on free
radicals10. Estrogen prevents platelet ag-
gregation by influencing the production
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of prostacyclin, which opposes thrombo-
xane.
6. Cardiovascular system – a 50% re-
duction in the relative risk of almost all
vascular events has thought to be associ-
ated with HRT, however, recent studies
found no significant decrease in the risk
of coronary events11; this may be related
to the fact that these studies used conju-
gated equine estrogens (CEE) + medroxy-
progesterone acetate (MPA).
7. Vasomotor effects – vascular bene-
fits include re-establishing the physiolog-
ical vasoactive response to ischemia, ex-
ercise or cold; estrogen may also exert
antihypertensive effects in premenopau-
sal women; other studies have revealed
that it increases both cerebral blood flow
and cerebral glucose utilization6.
8. Mood – estrogen influences brain
functions that potentially impact mood
and behavior, in general having a positive
effect. Older postmenopausal women who
use estrogen typically report fewer de-
pressive symptoms than non-users. Bene-
ficial effects of estrogen replacement on
mood are most often reported in healthy
women without diagnosed depression.
Among postmenopausal women in ran-
domized trials, active treatment reduced
depressive scores and had a substantial
beneficial influence on the quality of
life12. Other controlled studies, however,
reported no effect on mood13.
Stroke and HRT
Stroke remains the third leading cau-
se of mortality in developed countries and
the first cause of mortality in Croatia14.
Furthermore, stroke is the second cause
of dementia and the leading cause of long
-term disability. About 80% of strokes are
ischemic, 15% hemorrhagic and 5% of
other etiologies. Because stroke is often
fatal and the impact of treatment on pro-
gnosis is limited, control of the disease
should be through primary prevention.
Experimental studies have shown im-
provement in stroke outcome in animals
treated with hormones-estrogen seems to
exert neuroprotective effects15. After ex-
perimental carotid occlusion, female rats
have shown decreased cerebral infarcts
and less tissue damage than age-matched
male rats16. Additionally researchers found
that pretreatment of ovariectomized rats
with estradiol significantly reduced in-
farct volume following middle cerebral
artery occlusion, although acute treatment
had not17. Recent evidence suggests that
estrogen acts, in part, by increasing nitric
oxide (NO) in the cerebrovascular endo-
thelium; NO is produced by the enzyme
endothelial nitric oxide synthase (eNOS)
to cause vasodilatation and inhibit plate-
let aggregation18.
Since observational studies have shown
that HRT has been associated with a 35%
reduction in risk of chronic heart disease
(CHD), it has been suggested that HRT
may reduce stroke risk through modifica-
tion of intervening risk factors in the sim-
ilar way as it reduces the risk of CHD as
stroke and CHD share many risk fac-
tors19.
In the past 25 years, 26 observational
studies (in 37 articles) have evaluated the
effect of HRT on stroke risk in postmeno-
pausal women. Five case control studies,
which were examining the association of
HRT and risk of all strokes or ischemic
strokes, reported null effects, with rela-
tive risks ranging from 0.97 to 1.2020–24.
Among four uncontrolled cohort stud-
ies, two found a 20–50% reduced risk
(statistically significant) of stroke among
estrogen users, while in two there was
only a trend to reduction25–28. Among
twelve of the 15 internally controlled co-
hort studies, four found a reduction of
30% or more in stroke risk among estro-
gen users, and in eight there was a trend
to reduction29–32. According to these stud-
ies, the association of estrogen and stroke
is not consistent. The relative risk for to-
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tal stroke from all studies ranged from 0
to 3.2. Furthermore, surveys comparing
current users with never or past users did
not find any significant decrease in the
risk of coronary events, but found an in-
crease in transient ischemic attacks and
strokes23,33.
In 2001, Paganini-Hill summarized the
literature on HRT and stroke and con-
cluded that there was little, if any asso-
ciation34.
Some data indicate that estrogen us-
ers have a moderately reduced risk of fa-
tal stroke, but details about the optimal
dose, duration and type of estrogen are
insufficient34. Larger doses have shown
association with increased stroke risk26.
Recent data from the Nurses Health Stu-
dy (NHS) (observational cohort study in-
cluding 70,533 postmenopausal women)
have shown that risk of ischemic stroke
was significantly increased among those
women receiving 1.25 mg conjugated es-
trogen daily (RR = 2.1) as well as in wo-
men taking 0.625 mg daily (RR = 1.4),
but not in those receiving 0.3 mg daily
(RR = 0.4)35. Increased stroke risk may be
induced by the procoagulant effect of HRT
when using higher doses.
No clear trend (decreasing/increasing
risk) could be found in relation to dura-
tion of HRT in ischemic stroke but the
risk for fatal stroke seems to be reduced
in both long-term and short-term users24,32.
The Leisure World Study found risk of oc-
clusive stroke decreased with increasing
recency of use (for trend, p<0.05); women
who had used estrogen replacement ther-
apy within one year of study enrollment
had the lowest risk (RR = 0.7, p<0.05)36.
However, three other studies found no ef-
fect of current use on stroke risk (RR=
1.0–1.2) and 1 study showed increased
risk in current users (RR = 1.3) but not in
past users (RR = 1.0)21,23,24,35.
Evidence for effect of HRT on stroke is
most consistent for fatal stroke; all but
two of nine studies found at least 20% re-
duced risk in current users32,35,37–43. Both
low (<0.625 mg) and high (>1.25 mg) do-
ses of oral conjugated equine estrogens
were associated with significantly redu-
ced risk of fatal stroke (RR = 0.4)32. The
only apparent difference in the findings
of studies of fatal and non-fatal stroke
suggests that estrogen may prevent the
most lethal form of stroke or may im-
prove survival.
Reports of effect of HRT on SAH are
also differing. Two case control studies
found a 35–50% reduced risk among ever
users of estrogen (significant in one)44,45.
One uncontrolled cohort study found that
HRT was associated with a non-signifi-
cant increased risk of SAH (RR = 1.2)46.
In three studies hemorrhagic strokes
were analyzed together. No effect of estro-
gen therapy was found in two and in one
a significantly reduced risk in current
users20,24,36.
So far studies have not shown benefi-
cial effect of HRT in a stroke subtype
since most epidemiological studies have
grouped together all stroke subtypes. We
can speculate that HRT might affect risks
of stroke subtypes in a different way,
combining them would not show benefi-
cial effect but mask a positive effect in a
subgroup. This may be one of the reasons
for observed scattered relative risks in
epidemiological studies21,23,24,28. The pre-
ponderance of evidence in these studies
suggests however that HRT does not in-
crease the risk for stroke.
Several randomized, placebo control-
led studies have recently been published:
The Women’s Health Initiative (WHI)47,
Heart and Estrogen-progestin Replace-
ment Study (HERS)48,49, The Estrogen
Replacement and Atherosclerosis Trial
(ERA)50 and Women’s Estrogen for Stroke
Trial (WEST)51. We discuss these studies
more thoroughly.
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The Women’s Health Initiative trial
has been recognized as one of the most
important (and one of the largest) pre-
vention studies ever conducted. A total of
16,608 postmenopausal women aged 50–
79 years with an intact uterus were ran-
domly assigned to receive either CEE
0.625 mg and MPA 2.5 mg daily, or pla-
cebo. The third group of 10 739 hysterec-
tomized women received 0.625 mg CEE
(without progestin). After a mean of 5.2
years of follow-up the trial of estrogen
plus progestin vs. placebo was stopped
when the results met predetermined lev-
els of harm for breast cancer. The excess
risk of stroke in the estrogen plus pro-
gestin group was not present in the first
year but appeared during the second year
and persisted through the fifth year. No
interaction with age, ethnicity, body mass
index, prior hormone use, smoking sta-
tus, blood pressure, diabetes, aspirin or
statin use were found for the effect of es-
trogen plus progestin on CHD, stroke or
VTE (venous thromboembolism). There-
fore it appears that estrogen plus pro-
gestin increases the risk of stroke in ap-
parently healthy women. The trial re-
sults indicate that risk reduction attrib-
utable to this HRT regimen is low and not
beneficial overall; there is early harm for
CHD, continuing harm for stroke and
VTE, and increasing harm for breast can-
cer with increasing duration of treatment.
All –cause mortality was not affected dur-
ing the trial. The absolute excess risk
events included in the global index was
19 per 10,000/person years-in another
words – 1000 women would have to be
treated during 1 year in order to cause
two events. Beneficial effects were ob-
served for colorectal cancer and hip frac-
tures. This risk-benefit profile is not con-
sistent with the requirements for a viable
intervention for the primary prevention
of chronic disease. The WHI report stres-
ses that the results do not necessarily ap-
ply to lower dosages of those drugs, to
other formulations of oral estrogen and
progestin or other route of administra-
tion.
There was a high differential unbind-
ing rate in the WHI study (40.5% in the
HRT vs. 6.8% in the placebo group), most-
ly due to vaginal bleeding, but there was
no information about which of the age
groups had the bleeding. Thus this fixed
regimen of HRT is obviously not suitable
for all women, and does not reflect good
clinical practice47.
In HERS, a total of 2,763 postmeno-
pausal women with established coronary
disease was taking either 0.625 mg/d of
CEE plus 2.5 mg/d of MPA or placebo and
were followed-up for 4.1 years. The re-
sults showed no significant difference be-
tween groups in the primary outcome (oc-
currence of nonfatal myocardial infarc-
tion or CHD death (RR 0.99) or secondary
outcome (stroke or TIA, coronary revas-
cularization, unstable angina, congestive
heart failure, and peripheral artery dis-
ease). The results showed a statistically
significant time trend with more CHD
events in HRT group in year 1 and fewer
in years 4 and 5, thus the authors have
not recommended starting this treatment
for the purpose of secondary prevention
of CHD. Given the favorable pattern of
CHD events after several (4–5) years of
therapy, the authors assume it could be
appropriate for women already receiving
the treatment to continue. However, in a
re-analysis of the study (HERS II), fol-
low-up during 6.8 years of HRT has shown
that lower rates of CHD events among
women in the hormone group in the final
years of HERS did not persist during ad-
ditional years of follow-up. Furthermore,
more women in the hormone group than
in the placebo group experienced venous
thromboembolic events (RR 2.89) and
gallbladder disease (RR 1.38)48,49.
The Estrogen Replacement and Ath-
erosclerosis Trial (ERA), was the first
randomized angiographic end-point trial
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to test the effect of ERT and HRT on the
progression of atherosclerosis in postme-
nopausal women with documented coro-
nary stenosis. The results showed no ben-
efit of CEE (0.625 mg) + MPA (2.5 mg) on
angiographic progression of the disease.
An arm of the ERA trial tested a group of
women taking only estrogen vs. placebo,
the results showed no angiographic bene-
fit of the hormone group as well50.
In the Women’s Estrogen for Stroke
Trial of estradiol (without progestin)
(WEST), the first double blind, placebo-
controlled trial among postmenopausal in
women with prior stroke, no effect of es-
trogen on recurrent stroke or death was
found. Furthermore, women randomized
to estrogen had a significant increase in
the risk for fatal stroke and more severe
neurological impairments after stroke51.
The studies of HRT and stroke had a
number of potential biases: most data
were derived from observational studies
not randomized trials; the number of ca-
ses included was often very small reach-
ing low statistical power; confounding
factors such as concurrent medications
were often not considered; comparison
between – ever/never users was usually
made and not evaluating the duration of
use/current use etc; often not specific (va-
rying) definitions of stroke end-points
were used as well as specific stroke types
were not considered; HRT use patterns
were different among studies – estrogen,
progesterone, combination, doses, dura-
tion etc.
The problems of data interpretation
from observational studies due to the di-
versity of studies are well recognized,
however, the overall results and meta-
analysis of these studies should be taken
into consideration when giving final rec-
ommendations.
On the other hand, randomized, dou-
ble blind, placebo-controlled trials such
as WHI or HERS have failed to show ben-
efit of HRT in primary/secondary pre-
vention. Several explanation have been
suggested for the overall null effect: rela-
tively short time of follow up, adverse ef-
fects of MPA, bidirectional effects of es-
trogen (early risk and late benefit), a
combination of hormones (CEE+MPA)
that was not ideal for all women, a sub-
group of women too old to benefit from
such therapy. Randomized clinical trials
have inclusion and exclusion criteria much
more rigid than observational studies,
hence results are valid only for those who
meet those criteria.
Recommendations of the WHI writing
group and HERS trial are given on gen-
eral basis and focus on public rather than
individual health. The data describe in-
creased risk (stroke, VTE,) of general po-
pulation of women (healthy in WHI or
with CHD in HERS), but not the increa-
sed risk for individual woman. Although
WHI, HERS and similar studies are im-
portant, they only failed to show clinical
effectiveness of a specific hormone regi-
men in certain population groups. Never-
theless, a message sent from these stud-
ies is not to recommend HRT for the sole
purpose of chronic disease prevention
(primary or secondary).
It has been suggested that the results
of secondary prevention trials may not be
applicable to younger women because it
is less common for the occurrence of car-
diovascular events before the 6th decade
of life. Furthermore, one can hypothesize
that the development of CHD could be
more easily preventable than to slow the
progression once established if women
were given HRT early enough after me-
nopause. So far, no controlled trial ad-
dressed the timing of initiation of HRT on
rates of CHD events.
Alzheimer’s disease and HRT
During the past decade, a significant
number of studies have been conducted to
explore the possibility of a connection be-
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tween sex hormones and dementia52. Alz-
heimer’s disease (AD) is the most com-
mon dementing illness and is associated
with significant morbidity and mortality
among older adults53. Recent advances in
understanding neurophysiology have led
to the potential use of estrogen as an
agent that can favorably alter the patho-
biology of AD and may lead to improve-
ment of cognitive decline associated with
the disease.
Several biologic mechanisms by which
estrogen could affect cognitive function-
ing and dementia have been postulated.
Estrogen may affect the progression of
Alzheimer’s disease via its effects on the
metabolism of amyloidal precursor pro-
tein (APP) by reducing plaque forma-
tion54. Promotion of cholinergic activity in
the brain and stimulation of axonal sprou-
ting have been observed55,56. Estrogens
administered prior to a diagnosis of Alz-
heimer’s disease showed some positive ef-
fects due to its anti-inflammatory proper-
ties. Although estrogen has antioxidant
qualities, the hormone is thought to be
unable to slow progression of the disease
after onset. However, studies have shown
that women with AD taking estrogen per-
form better on a variety of cognitive tasks
than women with AD who are not taking
estrogens57,58.
Published trials of HRT for women di-
agnosed with Alzheimer’s disease have
produced conflicting evidence regarding
the potential benefits of the hormones.
Up to date no firm data can be offered
that HRT can be used as a treatment for
Alzheimer’s disease59. Recent randomi-
zed, double blind, placebo-controlled stu-
dies failed to show an enhancement of
cognitive function by estrogen. The Alz-
heimer’s Disease Cooperative Study, a
randomized, double blind placebo control-
led study included 120 women diagnosed
with mild to moderate Alzheimer’s dis-
ease who were taking two different dos-
ages of estrogens (0.625 mg or 1.25 mg
daily) or placebo for 12 months. A brief,
short-lived benefit was seen on Mini Men-
tal State Examination for women taking
low dose estrogen but no significant cog-
nitive or functional outcomes were noted
at the end of the study60. Other two stud-
ies were also negative; both used conju-
gated equine estrogens for periods of 12
and 16 weeks in small groups of patients
(n = 42; n = 50)61,62.
These studies have been criticized for
the small sample size, short duration of
HRT, use of inappropriate cognitive as-
sessment scales, presence of other risk
factors, older age of the subjects and ad-
vanced stage of the disease61,62.
However, there is more exciting data
on whether estrogen can be used against
longtime decline and development of the
disease. Recent evidence from epidemio-
logical studies indicates that estrogen re-
placement can significantly reduce the
risk for development of AD for postme-
nopausal women63,64.
Observational trials have shown that
estrogen improves cognitive performance
particularly in women without dementia,
or when estrogen was started prior to the
development of cognitive dysfunction. A
recent longitudinal study reported that
prolonged use of hormone replacement
therapy decreases the risk and delays the
onset of Alzheimer’s disease by 5% annu-
ally 65. In another study, risk for AD was
less pronounced in women ever-users of
estrogen than in never-users. In a popu-
lation cohort (n = 2,073) of older (aged
>65), non-demented women, lifetime HRT
exposure was associated with improved
global cognition and attenuated decline
over a 3-year interval 66. A study includ-
ing 7,705 postmenopausal women with
osteoporosis receiving 60 mg, 120 mg of
raloxifene or placebo for 3 years showed
no improvement in cognitive scores, al-
though there was a trend toward less de-
cline on tests of verbal memory and atten-
tion67.
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Several studies have attempted to ex-
plore the association between the blood
level of estrogen and cognitive decline in
postmenopausal women. Yaffe et al. re-
ported that higher concentrations of en-
dogenous estrogens prevent cognitive de-
cline; after 6 years of follow up, women in
highest tertile (according to free estradiol
levels) were three times less likely to
demonstrate cognitive decline than sub-
jects in the lowest tertile68. In a placebo
controlled trial, administration of higher
dose of estrogen (0.10 mg/day) was found
to enhance attention and memory for
postmenopausal women with Alzheimer’s
disease; however, women were followed
up for only 8 weeks69. Women who had
ever taken estrogens were one-third less
likely to develop Alzheimer’s disease. Ad-
ditionally, researchers noted that risk for
the disease decreases, as estrogen dos-
ages as well as duration of therapy were
increased70. Although these studies pro-
vide further clinical evidence to support
cognitive benefit of estrogen for women
with AD, longer treatment durations as
well as larger sample sizes and studies
evaluating the effect of estradiol adminis-
tration are further warranted.
It has been observed that Alzheimer’s
patients tend to be thinner than other
older persons, so hypothetically, body
weight might modify a woman’s risk of
Alzheimer’s disease71. In the Leisure
World study higher body weight at the
time of initial cohort enrollment was as-
sociated with a reduced likelihood of a
subsequent Alzheimer’s disease diagno-
sis72. It is possible however, that estradiol
levels were lowered as a result of women
having AD because of decrease of amount
of adipose tissue; a recent case-control
study showed that estradiol levels may
decline significantly in women with AD73.
In either way, it seems like estrogen plays
a role in cognitive functioning.
In general, women who received estro-
gen had a lower risk of developing AD,
but results are inconsistent. The cogni-
tive benefits of estrogen are confounded
by the observations that women who take
estrogen replacement therapy are often
younger, have higher education levels and
follow better nutritional and life-style
practices than women who do not choose
HRT. Only few studies establish the way
in which estrogen is administered, i.e. by
patch or by pill, and different presenta-
tions, i.e. estradiol or conjugated equine
estrogen; both possibly impacts the effi-
cacy and tolerance profiles for the treat-
ment of Alzheimer’s disease.
However, studies seem to provide evi-
dence of modest cognitive improvements,
although HRT regimens need to be stan-
dardized and replicated.
There may be a critical window in the
early stages of the disease when estrogen
therapy may prevent neuronal degenera-
tion. Early initiation of HRT seems to be
critical for cognitive benefits. Several ob-
servations support this view: accelerated
development of AD in women with pre-
mature natural menopause or surgical bi-
lateral ovariectomy, amelioration of Ab
deposition and inflammatory reaction in
ovariectomized animals by estrogen pre-
treatment, enhancement of cognitive
function in preadolescent girls with Tur-
ner’s syndrome by estrogen, observations
that women who started HRT in their for-
ties experienced significantly less cogni-
tive decline over time54,74–76. Therefore, it
has been suggested that estrogen therapy
may be more effective in the initiation
phase of neurodegeneration than in the
advanced stage.
Risks of HRT
The WHI trial is the first randomized
controlled trial to confirm that combined
estrogen plus progestin does increase the
risk of incident breast cancer (RR = 1,26);
because of the relatively short follow-up
time the WHI could not address the risk
of death due to breast cancer. A cumula-
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tive effect of years of exposure to hor-
mones is suggested since hazard ratio
was not higher in women with family his-
tory or other risk factors for breast cancer
(RR = 1,06)47. This is consistent with esti-
mates from pooled epidemiological data,
which reported a 15% increase of breast
cancer in estrogen plus progestin users
for less than 5 years and a 53% increase
for use over 5 years77. In HERS, non-sig-
nificant increase (RR = 1,26) was found
after 6.8 years of follow-up78. HERS also
showed increased risk for VTE (RR = 2,89)
and gallbladder disease (RR = 1,38)78. Risks
for development of endometrial cancer in-
creases with the length of estrogen ther-
apy: less than 1 year RR = 1,4; 5–9 years
RR = 5,9 and over 10 years RR = 9,579.
Estrogen dependent risk of endometrial
cancer may be abolished by the addition
of progestin80. This effect has been ob-
served in WHI where the RR was 0.8347.
Conclusions
There is no strong evidence that HRT
increases stroke, on the contrary, there is
some evidence that HRT may moderately
reduce the risk of fatal stroke. Unfortu-
nately, the majority of epidemiological
studies of HRT and stroke are observa-
tional studies with certain limitations.
Definite recommendations regarding op-
timal dose, duration and type of estrogen
cannot yet be established. Randomized,
placebo controlled trials are needed to
demonstrate more clearly the potential
benefits of estrogen and the cardiovascu-
lar/cerebrovascular system.
So far epidemiological, neuropsycho-
logical and biological studies support the
hypothesis that estrogens have a role in
the genesis and prevention of Alzheimer’s
disease. Results of some clinical trials of
HRT in patients with AD are promising
but need larger sample sizes, longer du-
ration of follow-up and more standardi-
zed assessment scales. Since recent trials
with Alzheimer’s disease and HRT have
been negative, it remains to be clarified
whether HRT may be used only as a pre-
ventive measure.
Several questions need answers: the
role of HRT as adjuvant therapy, should
estrogen be combined with progesterone
for positive cognitive effect, is transderm-
al versus oral HRT more beneficial, and
dosing regimens-alternating or long-term
steady exposure.
Advising postmenopausal women is
definitely not easy, it assumes giving the
best possible approach to preventive me-
dicine. Prescribing HRT must depend al-
ways on a benefit/risk analysis, which
means careful individual tailoring of the
therapy. Not all postmenopausal women
must necessarily be under HRT; the doc-
tor must assess which therapy is best
suitable for the individual woman- estro-
gen plus progestin, only estrogen, proper
dosage, right timing for commencement
of therapy, duration, risks.
HRT still has its primary indication
for relief of climacteric symptoms. The
stratification of individual risk should be
based on classical risk factors and algo-
rithms: »initiation and continuation of
HRT should be based on established non-
coronary benefits and risks, possible coro-
nary benefits and risks, and patient pref-
erence» (American Heart Association sta-
tement)81. If HRT is not suitable, non-
hormonal medications and alternative
strategies should be promoted. These in-
clude lifestyle changes including smoking
avoidance, proper nutrition (diet), regu-
lar exercise, drugs such as cholesterol
lowering statins (stabilization of the pla-
que), blood pressure medications (partic-
ularly ACE inhibitors) and if necessary
antiplatelet agents or anticoagulants81,82.
Finally, the answer to our question is
not easy and certainly not definite; how-
ever at this moment, having in mind re-
sults of given trials and the idea of good
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clinical practice, we conclude: HRT should
not be recommended on general basis for
the primary or secondary prevention of
cardiovascular/cerebrovascular diseases
or for primary prevention of degenerative
diseases such as Alzheimer’s disease. In-
dividual approach should be respected,
initiation and continuation of HRT should
be based on the benefit/risk ratio. Osteo-
porosis, cognitive decline and climacteric
symptoms that are likely to impact on
quality of life, speak in favor for recom-
mendation of HRT use. On the other side,
family history of breast carcinoma, ma-
stopathy, thromboembolism, in certain
cases gallbladder disease, will discourage
the commencement of HRT.
Respecting the patient’s preferences
and having benefits and risks in mind as
well as science advisory statements, indi-
vidual counseling regarding HRT should
be the leading concept in the healthcare
of postmenopausal women.
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HORMONALNO NADOMJESNO LIJE^ENJE I NJEGOVO MJESTO U
NEUROLOGIJI
S A @ E T A K
Usprkos trendu smanjivanja incidencije u posljednjim desetlje}ima, mo`dani udar
je i dalje tre}i uzrok smrti u razvijenim zemljama. S obzirom da je mo`dani udar vode}i
uzrok invaliditeta i drugi uzrok demencije, primarna prevencija bi trebala biti vode}i
oblik borbe protiv bolesti, jer dostupna terapija danas nije dovoljno u~inkovita. Zapa-
`eno je da estrogen ima protektivna svojstva koja mogu smanjiti rizik od mo`danog
udara, studije su me|utim pokazale opre~ne rezultate. Nema ~vrstih dokaza da hor-
monsko nadomjesno lije~enje (HNL) pove}ava rizik od mo`danog udara. U nekim stu-
dijama pokazalo se da HNL mo`e smanjiti rizik od fatalnog mo`danog udara. Opre~ni
rezultati su se tako|er pokazali i kod Alzheimerove bolesti i kori{tenja HNL. U nekim
studijama utvr|ena je povezanost vi{ih koncentracija serumskog estradiola i pobolj{a-
nja kognitivnih sposobnosti, {to podr`ava hipotezu da koncentracija estrogena mo`e
imati zna~ajnu ulogu u za{titi mo`danih funkcija. Imaju}i na umu rezultate randomi-
ziranih studija, predlo`eno je da se HNL ne bi trebalo op}enito preporu~ivati za pri-
marnu ili sekundarnu prevenciju kardiovaskularnih/cerebrovaskularnih bolesti kao i
degenerativnih bolesti kao {to je Alzheimerova bolest. Osteoporoza, smanjenje kogni-
tivnih sposobnosti i simptomi menopauze koji u ve}oj mjeri utje~u na kvalitetu `ivota
`ene, govore u prilog kori{tenja HNL. S druge strane, obiteljska anamneza karcinoma
dojke, mastopatija, tromboembolizam, u nekim slu~ajevima kolelitijaza, vjerojatnije }e
obeshrabriti potencijalne korisnice HNL. Po{tuju}i `elje pacijentice i imaju}i na umu
koristi i {tete kao i savjete stru~nih tijela, individualno savjetovanje u pogledu kori{te-
nja HNL trebalo bi biti vode}i koncept u zdravstvenom zbrinjavanju `ena u menopauzi.
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